Treatment of pulmonary hypertension (PH) in neonates is a major challenge on the intensive care unit and involves high morbidity and mortality. However we have gained considerable insights into the pathophysiology of PH leading to an increasing number of possible treatment targets. Translation of these novel targets into clinical application requires multi-centre randomized controlled trials. Furthermore, considering the underlying pathology is important in therapy choice. New therapies will not only target vasodilatation, but also reduce vascular remodeling and enhance postnatal lung development. This review provides an overview of currently available drugs and promising new targets in the treatment of PH in newborns.

D. Tibboel (Dick)
Erasmus University Rotterdam
FSC Mixed Sources
hdl.handle.net/1765/19546
Erasmus MC: University Medical Center Rotterdam

van der Horst, I.W.J.M. (2010, May 21). Congenital Diaphragmatic Hernia: A pulmonary vascular point of view. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/19546